347 related articles for article (PubMed ID: 30368223)
1. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
Rejdak K; Stelmasiak Z; Grieb P
Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis.
Koch M; Heersema D; Mostert J; Teelken A; De Keyser J
Eur J Neurol; 2007 Jul; 14(7):797-800. PubMed ID: 17594338
[TBL] [Abstract][Full Text] [Related]
3. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients.
Joseph FG; Hirst CL; Pickersgill TP; Ben-Shlomo Y; Robertson NP; Scolding NJ
J Neurol Neurosurg Psychiatry; 2009 Mar; 80(3):292-6. PubMed ID: 18829628
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
5. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
[TBL] [Abstract][Full Text] [Related]
8. Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients.
Stich O; Kluge J; Speck J; Rauer S
Acta Neurol Scand; 2015 Jun; 131(6):381-8. PubMed ID: 25402869
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the IgG index and oligoclonal bands in the cerebrospinal fluid of patients with multiple sclerosis.
Mares J; Herzig R; Urbanek K; Sladkova V; Sklenarova J; Bekarek V; Schneiderka P; Zapletalova J; Kanovsky P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):247-9. PubMed ID: 19219215
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and neurophysiologic findings in patients with multiple sclerosis without oligoclonal IgG in cerebrospinal fluid].
Mesaros S; Drulović J; Lević Z
Srp Arh Celok Lek; 2003; 131(3-4):122-6. PubMed ID: 14608874
[TBL] [Abstract][Full Text] [Related]
12. Associations of HLA DRB1 alleles with IgG oligoclonal bands and their influence on multiple sclerosis course and disability status.
Balnytė R; Rastenytė D; Vaitkus A; Skrodenienė E; Vitkauskienė A; Ulozienė I
Medicina (Kaunas); 2016; 52(4):217-222. PubMed ID: 27515835
[TBL] [Abstract][Full Text] [Related]
13. [Magnetic resonance findings in the brain of patients with multiple sclerosis without oligoclonal bands in the cerebrospinal fluid].
Mesaroc S; Drulović J; Lević Z; Perić V
Srp Arh Celok Lek; 2003; 131(1-2):31-5. PubMed ID: 14608859
[TBL] [Abstract][Full Text] [Related]
14. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
15. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
16. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
[TBL] [Abstract][Full Text] [Related]
18. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study.
Farina G; Magliozzi R; Pitteri M; Reynolds R; Rossi S; Gajofatto A; Benedetti MD; Facchiano F; Monaco S; Calabrese M
J Neuroinflammation; 2017 Feb; 14(1):40. PubMed ID: 28222766
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy.
Ferreira D; Voevodskaya O; Imrell K; Stawiarz L; Spulber G; Wahlund LO; Hillert J; Westman E; Karrenbauer VD
J Neuroimmunol; 2014 Sep; 274(1-2):149-54. PubMed ID: 24999245
[TBL] [Abstract][Full Text] [Related]
20. Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.
Halbgebauer S; Huss A; Buttmann M; Steinacker P; Oeckl P; Brecht I; Weishaupt A; Tumani H; Otto M
J Neurol; 2016 May; 263(5):954-960. PubMed ID: 26995358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
